S&P 500   4,164.00 (+1.29%)
DOW   34,156.69 (+0.78%)
QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
S&P 500   4,164.00 (+1.29%)
DOW   34,156.69 (+0.78%)
QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
S&P 500   4,164.00 (+1.29%)
DOW   34,156.69 (+0.78%)
QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
S&P 500   4,164.00 (+1.29%)
DOW   34,156.69 (+0.78%)
QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
NYSE:AMRX

Amneal Pharmaceuticals - AMRX Stock Forecast, Price & News

$2.70
+0.16 (+6.30%)
(As of 02/7/2023 04:35 PM ET)
Add
Compare
Today's Range
$2.46
$2.72
50-Day Range
$1.97
$2.61
52-Week Range
$1.95
$4.98
Volume
2.01 million shs
Average Volume
1.13 million shs
Market Capitalization
$819.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

Amneal Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
103.7% Upside
$5.50 Price Target
Short Interest
Bearish
8.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.51
Upright™ Environmental Score
News Sentiment
0.34mentions of Amneal Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$9.09 M Sold Last Quarter
Proj. Earnings Growth
18.97%
From $0.58 to $0.69 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.64 out of 5 stars

Medical Sector

79th out of 1,029 stocks

Pharmaceutical Preparations Industry

27th out of 504 stocks

AMRX stock logo

About Amneal Pharmaceuticals (NYSE:AMRX) Stock

Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generic, Specialty and AvKARE Segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The AvKARE segment focuses on pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.

Receive AMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amneal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMRX Stock News Headlines

Amneal Pharmaceuticals (NYSE:AMRX) Shares Up 4.8%
The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Amneal Pharmaceuticals
Amneal Pharmaceuticals: Risk Still Persists
The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Amneal to Participate at Upcoming Investor Conferences
Amneal Reports Third Quarter 2022 Financial Results
Amneal Pharmaceuticals: A Small 'Thumbs Up'
See More Headlines
Receive AMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amneal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMRX Company Calendar

Last Earnings
11/03/2021
Today
2/07/2023
Next Earnings (Confirmed)
3/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
7,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.50
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+103.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$10.62 million
Pretax Margin
-12.00%

Debt

Sales & Book Value

Annual Sales
$2.09 billion
Cash Flow
$1.76 per share
Book Value
$1.22 per share

Miscellaneous

Free Float
222,291,000
Market Cap
$819.69 million
Optionable
Optionable
Beta
1.33

Key Executives

  • Chintu Patel
    Co-Chief Executive Officer & Director
  • Chirag K. PatelChirag K. Patel
    President & Co-Chief Executive Officer & Director
  • Andrew S. Boyer
    Executive Vice President-Commercial Operations
  • Anastasios G. Konidaris
    Executive VP, Chief Financial & Accounting Officer
  • Nikita ShahNikita Shah
    Chief Human Resources Officer & Executive VP













AMRX Stock - Frequently Asked Questions

Should I buy or sell Amneal Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AMRX shares.
View AMRX analyst ratings
or view top-rated stocks.

What is Amneal Pharmaceuticals' stock price forecast for 2023?

1 analysts have issued 1-year price objectives for Amneal Pharmaceuticals' stock. Their AMRX share price forecasts range from $4.00 to $7.00. On average, they anticipate the company's share price to reach $5.50 in the next twelve months. This suggests a possible upside of 118.3% from the stock's current price.
View analysts price targets for AMRX
or view top-rated stocks among Wall Street analysts.

How have AMRX shares performed in 2023?

Amneal Pharmaceuticals' stock was trading at $1.99 at the beginning of the year. Since then, AMRX stock has increased by 26.6% and is now trading at $2.52.
View the best growth stocks for 2023 here
.

Are investors shorting Amneal Pharmaceuticals?

Amneal Pharmaceuticals saw a increase in short interest in the month of December. As of December 30th, there was short interest totaling 7,740,000 shares, an increase of 142.6% from the December 15th total of 3,190,000 shares. Based on an average daily volume of 1,140,000 shares, the short-interest ratio is currently 6.8 days. Currently, 7.8% of the company's stock are short sold.
View Amneal Pharmaceuticals' Short Interest
.

When is Amneal Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our AMRX earnings forecast
.

How can I listen to Amneal Pharmaceuticals' earnings call?

Amneal Pharmaceuticals will be holding an earnings conference call on Thursday, March 2nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 866-813-9403 with passcode "942331".

How were Amneal Pharmaceuticals' earnings last quarter?

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) posted its quarterly earnings results on Wednesday, November, 3rd. The company reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.01. The business had revenue of $528.30 million for the quarter, compared to analysts' expectations of $544.08 million. Amneal Pharmaceuticals had a positive trailing twelve-month return on equity of 57.89% and a negative net margin of 6.17%. Amneal Pharmaceuticals's revenue for the quarter was up 1.7% on a year-over-year basis. During the same period in the prior year, the business earned $0.16 earnings per share.

What guidance has Amneal Pharmaceuticals issued on next quarter's earnings?

Amneal Pharmaceuticals updated its FY22 earnings guidance on Tuesday, January, 10th. The company provided earnings per share (EPS) guidance of $0.65-0.70 for the period, compared to the consensus earnings per share estimate of $0.66. The company issued revenue guidance of $2.15-2.25 billion, compared to the consensus revenue estimate of $2.18 billion.

What is Chirag and Chintu Patel's approval rating as Amneal Pharmaceuticals' CEO?

23 employees have rated Amneal Pharmaceuticals Chief Executive Officer Chirag and Chintu Patel on Glassdoor.com. Chirag and Chintu Patel has an approval rating of 91% among the company's employees. This puts Chirag and Chintu Patel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amneal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amneal Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Teva Pharmaceutical Industries (TEVA), Cisco Systems (CSCO), Micron Technology (MU), General Electric (GE), OPKO Health (OPK), Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV) and Bausch Health Companies (BHC).

What is Amneal Pharmaceuticals' stock symbol?

Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX."

Who are Amneal Pharmaceuticals' major shareholders?

Amneal Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.52%), Strs Ohio (0.07%), Los Angeles Capital Management LLC (0.06%), Assenagon Asset Management S.A. (0.02%), Hennion & Walsh Asset Management Inc. (0.02%) and Hedges Asset Management LLC (0.02%). Insiders that own company stock include Chintu Patel, Chirag K Patel, Gautam Patel, Jeffrey P George, John Kiely, Joseph Todisco, Nikita Shah, Paul M Meister and Tpg Gp A, Llc.
View institutional ownership trends
.

How do I buy shares of Amneal Pharmaceuticals?

Shares of AMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amneal Pharmaceuticals' stock price today?

One share of AMRX stock can currently be purchased for approximately $2.52.

How much money does Amneal Pharmaceuticals make?

Amneal Pharmaceuticals (NYSE:AMRX) has a market capitalization of $765.05 million and generates $2.09 billion in revenue each year. The company earns $10.62 million in net income (profit) each year or ($0.87) on an earnings per share basis.

How many employees does Amneal Pharmaceuticals have?

The company employs 7,000 workers across the globe.

How can I contact Amneal Pharmaceuticals?

Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The official website for the company is www.amneal.com. The company can be reached via phone at (908) 947-3120, via email at invest@amneal.com, or via fax at 908-947-3146.

This page (NYSE:AMRX) was last updated on 2/7/2023 by MarketBeat.com Staff